A generic version of Novartis’ blockbuster cancer drug Gleevec (imatinib) hit the market in January, and if doctors use it instead of the pricier version, the U.S. health system would save $100,000 per patient over five years. That’s the conclusion of a new study from the Johns Hopkins Bloomberg School of Public Health. The savings for one insurance company treating just 100 patients with the drug over five years? The researchers conclude that would be an eye-popping $9.1 million.
